🟢 100/100

This product looks safe

  • No ingredients exceed tolerable upper intake levels
  • 67% of ingredients have research evidence
A Label Compliance Grade

Product Label

📸

Have a supplement label? Find it here.

Upload a photo of any supplement label to search our database of 92,312 products.

Label Data

2 Tablet(s) Serving Size
60 Servings
Other Combinations Product Type
67% Evidence Coverage

Supplement Facts — Evidence Check

150 mg (38% DV)
📊 Market median: 4002.0mg (1 products) 📚 20 studies (Tier A: 0, B: 2)
This product: 150mg
10 mg (67% DV)
✅ Within RDA (0.9× RDA of 11 mg) 📚 258 studies (Tier A: 6, B: 134)
RDA 11mg This product: 10mg UL 40mg
StAR-P2
2238 mg

Other Ingredients

Microcrystalline Cellulose Stearic Acid Povidone Hydroxypropyl Methyl Cellulose Polyethyene Glycol

Label Claims — Verification

All Other
Structure/Function
All Other (99% of products) Structure/Function (85% of products) Nutrient (54% of products) Approved Health (3% of products)

Target Groups

Adult (18 - 50 Years)

Product Information

📋 Directions for Use

Important: Use Axis-HT for at least 6 weeks in order to fully maximize its anabolic-androgenic potential. Do not exceed 12 weeks of coninuous use.

NOTE: If a reduction in androgenic effects is desired, cut dosage in half.

RECOMMENDED USE: As a dietary supplement, take 2 tablets 3 times per day, everyday. Take the first dose in the morning with breakfast, the second with lunch, and the third at night with your last meal. Axis-HT works synergistically with protein and carbohydrates to help promote muscle anabolism. It is therefore highly recommended that you take Axis-HT with a protein and carbohydrate-rich meal or shake. Stack Axis-HT with NO-Xplode, CellMass, and Nitrix.

⚠️ Warnings & Precautions

Keep out of reach of children.

Do not use if you are pregnant or nursing.

After 12 weeks of use discontinue for at least 4 weeks.

Not intended for use by persons under the age of 18.

Reduce or dicontinue use if excessive sleeplessness, tremors, dizziness, nervousness, headaches, or heart palpitations occur. For use by healthy adults only.

WARNING: Seek advice from a health care practitioner prior to use if you have any pre-existing medical condition including, but not limited to: hypertension, hypotension, heart, liver, or thryoid disease, prostate hypertrophy, diabetes, psychological disorders, asthma, pernicious anemia, anxiety, depression, seizure disorder, cardiac arrhythmia, stroke, difficulty urinating due to prostate enlargement, or if you are taking an MAO inhibitor or any other prescription drug.

Additional Information

A Designer Anabolic & Androgenic Potentiator*

Pro-Testosterone Amplifier

SIZE* - STRENGTH* - HARDNESS* - LIBIDO*

V.1.305.0705US

Product Details

UPC / SKU 8 34266 00305 1
DSLD Entry Date 2011-11-25
Product Type Other Combinations
Form Tablet or Pill
Brand BSN
DSLD ID 2296
Data Updated 2026-04-11

Research Evidence

849 Research Sources
56 Avg Quality Score
450 Meta Analysis
152 Rct
137 Systematic Review
73 Clinical Trial
11 Regulatory Source
7 Other
7 Guideline
3 Openfda Safety
2 Cochrane Review
2 Observational
A Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD)
Meta Analysis The Cochrane database of systematic reviews 2018
A Calcium supplementation (other than for preventing or treating hypertension) for improving pregnancy and infant outcomes
Meta Analysis The Cochrane database of systematic reviews 2024
A Calcium supplementation (other than for preventing or treating hypertension) for improving pregnancy and infant outcomes
Meta Analysis The Cochrane database of systematic reviews 2015
A Vitamin and mineral supplementation for maintaining cognitive function in cognitively healthy people in mid and late life
Meta Analysis The Cochrane database of systematic reviews 2018
A Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems
Meta Analysis The Cochrane database of systematic reviews 2025
A Dietary calcium supplementation for preventing colorectal cancer and adenomatous polyps
Systematic Review The Cochrane database of systematic reviews 2008
A Calcium and vitamin D for increasing bone mineral density in premenopausal women
Systematic Review The Cochrane database of systematic reviews 2023
A Dietary sodium, sodium-to-potassium ratio, and risk of stroke: A systematic review and nonlinear dose-response meta-analysis
Meta Analysis Clinical nutrition (Edinburgh, Scotland) 2019
A The association between circulating magnesium and clinically relevant outcomes in patients with chronic kidney disease: A systematic review and meta-analysis
Meta Analysis Clinical nutrition (Edinburgh, Scotland) 2021
A Calcium channel blockers versus other classes of drugs for hypertension
Systematic Review The Cochrane database of systematic reviews 2021
View all evidence for Electrolytes →

Compare Similar Products

View all Electrolytes products →